Authors: Atsunari Kawashima, Hitoshi Takayama, Norihiko Kawamura, Noriteru Doi, Mototaka Sato, Koji Hatano, Akira Nagahara, Motohide Uemura, Yasutomo Nakai, Kensaku Nishimura, Susumu Miyoshi, Kiyoshi Kawano, Kazuo Nishimura, Norio Nonomura, Akira Tsujimura
Affiliations: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Urology, Osaka Rosai Hospital, Sakai, Japan, Department of Pathology, Osaka Rosai Hospital, Sakai, Japan, Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
Published online on: Monday, April 23, 2012
Neoadjuvant chemotherapy (NC) for bladder cancer has been reported to significantly improve the 5-year survival rate. The aim of the present study was to examine the roles of ERCC1 and Snail in determining the response to chemotherapy in bladder cancer treated with NC and radical cystectomy (RC). The expression of the Snail and ERCC1 proteins was determined by immunohistochemical staining of specimens obtained from 58 patients with bladder tumors treated with NC and RC. The correlation between clinical response and the expression of Snail and ERCC1 was investigated. Snail and ERCC1 were co-expressed in 24 (41.4%) of the 58 patients. A marked correlation was found between the expression of Snail and ERCC1 (P=0.001). The co-expression of Snail and ERCC1 was not able to predict pathological complete response (P=0.202). Results of the univariate analysis revealed that the co-expression of Snail and ERCC1 predicted shorter disease-free survival (DFS) and overall survival (OS) than the negative expression of Snail and/or ERCC1. Moreover, the co-expression of ERCC1 and Snail was the only predictive factor for both DFS (P=0.029) and OS (P=0.040). The expression of Snail was correlated with that of ERCC1 and the co-expression of Snail and ERCC1 was the only significant predictive factor of shorter DFS and OS in patients with bladder cancer treated with NC and RC.